posted by AHIP
on May 16, 2019
On May 16, 2019, AHIP submitted a statement for a House Oversight and Reform Committee hearing on the excessive list price set and controlled exclusively by Gilead Sciences, Inc. for Truvada, its HIV prevention drug, for pre-exposure prophylaxis (PrEP).
Our statement emphasizes that out-of-control prices for Truvada—and innumerable other prescription drugs—are a direct consequence of drug makers taking advantage of a broken market for their own financial gain at the expense of patients. While discussing the importance of ensuring that PrEP is available to high-risk individuals at an affordable price, we express concern that Truvada—the only FDA-approved PrEP drug currently available—carries a list price approaching $2,000 per month (or about $70 per daily pill).
We also discuss our support for market-based solutions that hold drug makers accountable for high list prices and put downward pressure on prescription drug prices through competition, consumer choice, and open and honest drug pricing.